Posting of Circular and Notice of AGM
Renalytix plc has posted a shareholder circular and notice of a General Meeting to approve resolutions related to a fundraising, with the meeting scheduled for September 28, 2026. Directors recommend shareholders vote in favour of these resolutions, and they intend to do so for their own holdings, which represent 5.5% of the company's current issued share capital.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 8 September, 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company focused on kidney disease, confirms that, further to the Company's announcement released at 07:01 on 1 September 2026 (RNS Number: 8254S), a shareholder circular, containing the Notice of the General Meeting setting out the Resolutions and further details on the Fundraising, has been posted to Shareholders and is available on the Company's website at https://investors.renalytix.com/documents/.
The General Meeting to approve the Resolutions will be held at 12.00 p.m. on 28 September 2026 at 1 Bow Churchyard, London EC4M 9DQ.
The Circular includes a recommendation from Directors that all Shareholders of the Company vote in favour of the Resolutions, as they intend to do in respect of their own holdings of Ordinary Shares representing 5.5 per cent. of the current issued share capital of the Company.
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company dedicated to optimizing kidney disease management through precision-based care intervention. It's KidneyIntelX™ technology and data-driven insights help clinical teams understand patient level of risk for progressive decline in kidney function in the earliest stages of diabetic kidney disease. This enables clinicians to focus resources and guideline-recommended treatment, providing the best chance for improving kidney and overall renal-cardio-metabolic outcomes.
Renalytix has been granted FDA authorization and Medicare reimbursement for kidneyintelX.dkd which is offered commercially throughout the United States. For more information about the kidneyintelX.dkd test, visit www.kidneyintelx.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.